KR100763064B1 - 제약 조성물 및 용도 - Google Patents

제약 조성물 및 용도 Download PDF

Info

Publication number
KR100763064B1
KR100763064B1 KR1020017014807A KR20017014807A KR100763064B1 KR 100763064 B1 KR100763064 B1 KR 100763064B1 KR 1020017014807 A KR1020017014807 A KR 1020017014807A KR 20017014807 A KR20017014807 A KR 20017014807A KR 100763064 B1 KR100763064 B1 KR 100763064B1
Authority
KR
South Korea
Prior art keywords
bisphosphonates
diphosphonic acid
acid
angiogenesis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017014807A
Other languages
English (en)
Korean (ko)
Other versions
KR20010113830A (ko
Inventor
데쯔지 오꾸노
조나단 그린
지네트 마르조리에 우드
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100763064(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9911926.5A external-priority patent/GB9911926D0/en
Priority claimed from GBGB9925131.6A external-priority patent/GB9925131D0/en
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20010113830A publication Critical patent/KR20010113830A/ko
Application granted granted Critical
Publication of KR100763064B1 publication Critical patent/KR100763064B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020017014807A 1999-05-21 2000-05-19 제약 조성물 및 용도 Expired - Fee Related KR100763064B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9911926.5A GB9911926D0 (en) 1999-05-21 1999-05-21 Organic compounds
GB9911926.5 1999-05-21
GB9925131.6 1999-10-22
GBGB9925131.6A GB9925131D0 (en) 1999-10-22 1999-10-22 Organic compounds

Publications (2)

Publication Number Publication Date
KR20010113830A KR20010113830A (ko) 2001-12-28
KR100763064B1 true KR100763064B1 (ko) 2007-10-04

Family

ID=26315578

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017014807A Expired - Fee Related KR100763064B1 (ko) 1999-05-21 2000-05-19 제약 조성물 및 용도

Country Status (21)

Country Link
US (2) US20020142996A1 (enExample)
EP (1) EP1178810B8 (enExample)
JP (1) JP2003500352A (enExample)
KR (1) KR100763064B1 (enExample)
CN (1) CN1202828C (enExample)
AT (1) ATE293450T1 (enExample)
AU (1) AU775079B2 (enExample)
BR (1) BR0010808A (enExample)
CA (1) CA2374049A1 (enExample)
DE (1) DE60019580T2 (enExample)
DK (1) DK1178810T3 (enExample)
ES (1) ES2240106T3 (enExample)
HU (1) HUP0201329A3 (enExample)
IL (2) IL146520A0 (enExample)
NO (1) NO322212B1 (enExample)
NZ (1) NZ515541A (enExample)
PL (1) PL351674A1 (enExample)
PT (1) PT1178810E (enExample)
SK (1) SK16682001A3 (enExample)
TW (1) TWI224504B (enExample)
WO (1) WO2000071104A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1296689T3 (da) * 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
EP1591122B1 (en) * 2000-06-20 2012-09-26 Novartis AG Method of administering bisphosphonates
DE60143964D1 (de) * 2001-02-06 2011-03-10 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
BR0209365A (pt) * 2001-05-02 2004-06-08 Novartis Ag Usos farmacêuticos de bisfosfonatos
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
BR0308901A (pt) 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
ATE441420T1 (de) * 2002-12-02 2009-09-15 Innate Pharma Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
US20060281714A1 (en) * 2003-07-21 2006-12-14 Johann Zimmermann Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
US7618953B2 (en) † 2004-02-26 2009-11-17 Zentiva, A.S. Amorphous forms of risedronate monosodium
ES2358269T3 (es) * 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
US7914810B2 (en) 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2015018659A1 (en) * 2013-08-05 2015-02-12 Vib Vzw Glutamine synthetase inhibitors for inhibition of pathological angiogenesis
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608368A (en) * 1984-07-13 1986-08-26 Henkel Kommanditgesellschaft Auf Aktien 1-hydroxy-1,1-diphosphonic acids and cytostatic use thereof
EP0252504A1 (de) * 1986-07-11 1988-01-13 Roche Diagnostics GmbH Neue Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
SE9402001D0 (sv) * 1994-06-09 1994-06-09 Leiras Oy Pyridylbisphosphonates for use as a therapeutical agent
IT1290444B1 (it) * 1997-03-27 1998-12-03 Boehringer Mannheim Italia Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale
DE69803291T2 (de) * 1997-07-22 2002-08-08 Merck & Co Inc Methoden zur verhinderung von knochenresorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EP0998934A4 (en) * 1997-12-25 2005-09-14 Toray Industries REMEDIES AGAINST INTRAMEDULLARY DISEASES
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
WO1999038998A1 (en) * 1998-01-29 1999-08-05 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608368A (en) * 1984-07-13 1986-08-26 Henkel Kommanditgesellschaft Auf Aktien 1-hydroxy-1,1-diphosphonic acids and cytostatic use thereof
EP0252504A1 (de) * 1986-07-11 1988-01-13 Roche Diagnostics GmbH Neue Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EP 252504 A1.
Leukemia and Lymphoma, Vol.32, Np.1-2, pp.129-138, 1998.
Proceddings of the American Association for Cancer Research, Vol.37, p58, abstract #404, 1996.3.
US 4608368 A.
US 5358941 A.

Also Published As

Publication number Publication date
PL351674A1 (en) 2003-05-19
IL146520A0 (en) 2002-07-25
WO2000071104A3 (en) 2001-07-19
NO322212B1 (no) 2006-08-28
DK1178810T3 (da) 2005-07-11
CA2374049A1 (en) 2000-11-30
DE60019580D1 (de) 2005-05-25
SK16682001A3 (sk) 2002-04-04
CN1202828C (zh) 2005-05-25
JP2003500352A (ja) 2003-01-07
BR0010808A (pt) 2002-08-27
HUP0201329A2 (en) 2002-08-28
NO20015638D0 (no) 2001-11-19
EP1178810A2 (en) 2002-02-13
IL146520A (en) 2006-09-05
NO20015638L (no) 2002-01-15
EP1178810B1 (en) 2005-04-20
NZ515541A (en) 2003-03-28
CN1384749A (zh) 2002-12-11
US20040176327A1 (en) 2004-09-09
TWI224504B (en) 2004-12-01
WO2000071104A2 (en) 2000-11-30
HUP0201329A3 (en) 2005-02-28
ATE293450T1 (de) 2005-05-15
AU5214100A (en) 2000-12-12
ES2240106T3 (es) 2005-10-16
PT1178810E (pt) 2005-08-31
AU775079B2 (en) 2004-07-15
KR20010113830A (ko) 2001-12-28
US20020142996A1 (en) 2002-10-03
EP1178810B8 (en) 2005-07-27
DE60019580T2 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
EP1178810B1 (en) Use of bisphosphonic acids for treating angiogenesis
AU2001274109B2 (en) Method of administering bisphosphonates
RU2297229C2 (ru) Фармацевтическое применение бисфосфонатов
US5965547A (en) Use of certain methanebishosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
US20040063670A1 (en) Use of bisphosphonates for pain treatment
JP2003500352A5 (enExample)
CN1327844C (zh) 包含双膦酸类化合物和hmg－coa还原酶抑制剂的组合疗法
US20020061866A1 (en) Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
RU2261100C2 (ru) Применение бисфосфоновых кислот для лечения ангиогенеза
EP1591122A1 (en) Method of administering bisphosphonates
CA2183764C (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
HK1080734B (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080416

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1007630640000

Gazette reference publication date: 20071004

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100922

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100922

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000